Minimal residual disease in ovarian cancer as a target for complement-mediated mAb immunotherapy

Scandinavian Journal of Immunology

Volumn 63, Issue 5, 2006, Pages 355-364

  Bjorge L ^a,b,c,d   Stoiber, H ^c   Dierich, M P ^c   Meri, S ^d  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; COMPLEMENT; DECAY ACCELERATING FACTOR; KI 67 ANTIGEN; MONOCLONAL ANTIBODY;

ANTIGEN EXPRESSION; ARTICLE; CELL CYCLE G0 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DNA DETERMINATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MINIMAL RESIDUAL DISEASE; OVARY CANCER; PERITONEAL CAVITY; PRIORITY JOURNAL; TUMOR CELL;

ADENOCARCINOMA; ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; ANTIGENS, CD55; ANTIGENS, NEOPLASM; CELL CYCLE; CELL LINE, TUMOR; COMPLEMENT SYSTEM PROTEINS; DNA, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY; KI-67 ANTIGEN; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS;

EID: 33646254114     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2006.01751.x     Document Type: Article

References (44)

1. Gorter A Meri S Immune evasion of tumor cells using membrane-bound complement regulatory proteins Immunol Today 1999 20 576 82
2. Morgan BP Meri S Membrane proteins that protect against complement lysis Springer Semin Immunopathol 1994 15 369 96
3. Walport MJ Complement. First of two parts N Engl J Med 2001 344 1058 66
4. Morgan BP Effects of the membrane attack complex of complement on nucleated cells Curr Top Microbiol Immunol 1992 178 115 40
5. Junnikkala S Hakulinen J Jarva H et al. Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumour cells Br J Cancer 2002 87 1119 27
6. Junnikkala S Jokiranta TS Friese MA Jarva H Zipfel PF Meri S Exceptional resistance of human H2 glioblastoma cells to complement-mediated killing by expression and utilization of factor H and factor H-like protein 1 J Immunol 2000 164 6075 81
7. Dubeau L The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes? Gynecol Oncol 1999 72 437 42
8. Bjorge T Engeland A Hansen S Trope CG Prognosis of patients with ovarian cancer and borderline tumours diagnosed in Norway between 1954 and 1993 Int J Cancer 1998 75 663 70
9. Baekelandt MM Holm R Nesland JM Trope CG Kristensen GB P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer Anticancer Res 2000 20 1061 7
10. Kristensen GB Trope C Epithelial ovarian carcinoma Lancet 1997 349 113 7
11. Braun S Schindlbeck C Hepp F et al. Occult tumor cells in bone marrow of patients with locoregionally restricted ovarian cancer predict early distant metastatic relapse J Clin Oncol 2001 19 368 75
12. Cain JM Ellis GK Collins C et al. Bone marrow involvement in epithelial ovarian cancer by immunocytochemical assessment Gynecol Oncol 1990 38 442 5
13. Dauplat J Hacker NF Nieberg RK Berek JS Rose TP Sagae S Distant metastases in epithelial ovarian carcinoma Cancer 1987 60 1561 6
14. Pantel K Cote RJ Fodstad O Detection and clinical importance of micrometastatic disease J Natl Cancer Inst 1999 91 1113 24
15. Barnhill RL Piepkorn MW Cochran AJ Flynn E Karaoli T Folkman J Tumor vascularity, proliferation, and apoptosis in human melanoma micrometastases and macrometastases Arch Dermatol 1998 134 991 4
16. Dillman RO Antibodies as cytotoxic therapy J Clin Oncol 1994 12 1497 515
17. Scott AM Welt S Antibody-based immunological therapies Curr Opin Immunol 1997 9 717 22
18. Braun S Hepp F Sommer HL Pantel K Tumor-antigen heterogeneity of disseminated breast cancer cells: implications for immunotherapy of minimal residual disease Int J Cancer 1999 84 1 5
19. Braun S Pantel K Biological characteristics of micrometastatic cancer cells in bone marrow Cancer Metastasis Rev 1999 18 75 90
20. Braun S Pantel K Micrometastatic bone marrow involvement: detection and prognostic significance Med Oncol 1999 16 154 65
21. Muto MG Kassis AI Monoclonal antibodies used in the detection and treatment of epithelial ovarian cancer Cancer 1995 76 2016 27
22. Rubin SC Monoclonal antibodies in the management of ovarian cancer. A clinical perspective Cancer 1993 71 1602 12
23. Bookman MA Darcy KM Clarke-Pearson D Boothby RA Horowitz IR Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a Phase II trial of the Gynecologic Oncology Group J Clin Oncol 2003 21 283 90
24. Goodman GE Hellstrom I Brodzinsky L et al. Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian, and lung cancer J Clin Oncol 1990 8 1083 92
25. Riethmuller G Schneider-Gadicke E Schlimok G et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group Lancet 1994 343 1177 83
26. Bjorge L Hakulinen J Wahlstrom T Matre R Meri S Complement-regulatory proteins in ovarian malignancies Int J Cancer 1997 70 14 25
27. Bjorge L Junnikkala S Kristoffersen EK Hakulinen J Matre R Meri S Resistance of ovarian teratocarcinoma cell spheroids to complement-mediated lysis Br J Cancer 1997 75 1247 55
28. Hakulinen J Meri S Expression and function of the complement membrane attack complex inhibitor protectin (CD59) on human breast cancer cells Lab Invest 1994 71 820 7
29. Jurianz K Ziegler S Garcia-Schuler H et al. Complement resistance of tumor cells: basal and induced mechanisms Mol Immunol 1999 36 929 39
30. Hakulinen J Meri S Complement-mediated killing of microtumors in vitro Am J Pathol 1998 153 845 55
31. Brasoveanu LI Altomonte M Fonsatti E et al. Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells Lab Invest 1996 74 33 42
32. Golay J Zaffaroni L Vaccari T et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis Blood 2000 95 3900 8
33. Caldani C Far DF Birtwisle-Peyrottes I Ettore F Rostagno P Cell cycle expression of p53 protein, c-Myc gene product and tyrosine-phosphorylation level determined by image analysis in human breast cancer cells Anal Quant Cytol Histol 1996 18 233 40
34. Furukawa Y Cell cycle regulation of hematopoietic stem cells Hum Cell 1998 11 81 92
35. Koretz K Bruderlein S Henne C Moller P Expression of CD59, a complement regulator protein and a second ligand of the CD2 molecule, and CD46 in normal and neoplastic colorectal epithelium Br J Cancer 1993 68 926 31
36. Hosch SB Scheunemann P Luth M et al. Expression of 17-1A antigen and complement resistance factors CD55 and CD59 on liver metastasis in colorectal cancer J Gastrointest Surg 2001 5 673 9
37. Marth C Zeimet AG Widschwendter M Daxenbichler G Regulation of CA 125 expression in cultured human carcinoma cells Int J Biol Markers 1998 3 207 9
38. Chhieng DC Rodriguez-Burford C Talley LI et al. Expression of CEA, Tag-72, and Lewis-Y antigen in primary and metastatic lesions of ovarian carcinoma Hum Pathol 2003 34 1016 21
39. Dyatlovitskaya EV Andreasyan GO Malykh YaN Rylova SN Somova OG Ganglioside shedding and changes in ceramide biosynthesis in human ovarian tumors Biochemistry 1997 62 557 61
40. Weiner LM An overview of monoclonal antibody therapy of cancer Semin Oncol 1999 26 41 50
41. Schultes BC Baum RP Niesen A Noujaim AA Madiyalakan R Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1) Cancer Immunol Immunother 1998 46 201 12
42. Donin N Jurianz K Ziporen L Schultz S Kirschfink M Fishelson Z Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid Clin Exp Immunol 2003 131 254 63
43. Holmberg MT Blom AM Meri S Regulation of complement classical pathway by association of C4b-binding protein to the surfaces of SK-OV-3 and Caov-3 ovarian adenocarcinoma cells J Immunol 2001 167 935 9
44. Rus HG Niculescu F Shin ML Sublytic complement attack induces cell cycle in oligodendrocytes J Immunol 1997 156 4892 900